Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

49.13 -0.23 (-0.47%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi-Aventis S.A. ADR

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
26 27 Next >
Sanofi (NASDAQ: SNY) Highlighted for Surprising Price Action
Via Investor Brand Network
Why Shares of Regeneron Are Rising Thursday
Regeneron released positive phase 3 trial results for its therapy Dupixent. 
Via The Motley Fool
REGN Stock Alert: Regeneron Pharmaceuticals Gains on Dupixent Drug Data
Regeneron Pharmaceuticals (REGN) stock is on the rise Thursday after the company released its latest clinical trial data on Dupixent. 
Via InvestorPlace
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Oak Street Health (NYSE – OSH), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)
From Brodsky & Smith LLC
Via GlobeNewswire
Regeneron, Sanofi Soar On Blow-Out Results In 'Smoker's Lung'
The companies' Dupixent reduced exacerbations by 30%. 
Via Investor's Business Daily
Acer Therapeutics' Product Acquired From Sanofi Fails In Menopause Study
Via Benzinga
2 Top Biotech Stocks to Buy Right Now
These two companies are showering shareholders with market-topping payouts. 
Via The Motley Fool
Apple Jumps Movie Production Bandwagon, Billionaire Jim Ratcliffe Bids For Manchester United, Elon Musk Seeks Funding For SpaceX From Middle-Eastern Fund: Today's Top Stories
Bloomberg 
Via Benzinga
Why Regeneron Pharmaceuticals And Sanofi Shares Are Trading Higher Today
Sanofi-Regeneron stocks are trading higher today after their blockbuster drug aced the pivotal COPD trial. 
Via Benzinga
Credit Suisse's $17B Of AT1 Debt Written Down To Zero, Richard Branson's Virgin Orbit Plans Insolvency, Court Freezes Volkswagen's Russian Assets: Today's Top Stories
Reuters 
Via Benzinga
Large Vaccine Players Including GSK, Moderna Prepare For Bird Flu Vaccine 'Just In Case'
Via Benzinga
Provention Bio's $2.9B Acquisition - A Strategic Fit For Sanofi
Via Benzinga
How Is The Market Feeling About Sanofi?
Via Benzinga
Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Stock Market Diverges Amid Bank Woes, Growth Gains; First Republic, Credit Suisse, Meta In Focus: Weekly Review
A market rally is underway, but bank stocks kept tumbling. 
Via Investor's Business Daily
SVB Financial Officially Files For Bankruptcy, Yellen, Powell & Dimon Behind First Republic Bank's $30B Lifeline, Playboy's $5M Loss On Ethereum: Today's Top Stories
Benzinga 
Via Benzinga
Three Is Company - Sanofi Follows Lilly, Novo Nordisk, Slashes Insulin Product Price By 78%
Via Benzinga
Why Provention Bio Stock Skyrocketed 256% This Week
Provention Bio is currently a partner of Sanofi. It should soon become a part of the big French drugmaker. 
Via The Motley Fool
What's Going On With Sanofi Stock After Hours?
Sanofi SA (NASDAQ: SNY) is buzzing in Thursday's after-hours session after the company said it will cut the list price of its most widely prescribed insulin in the United States  
Via Benzinga
Monday Merger Mania Just Made These 2 Biotech Stocks Big Winners
On a volatile market day, companies are still looking for smart combinations. 
Via The Motley Fool
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Qualtrics (Nasdaq - XM), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)
From Brodsky & Smith LLC
Via GlobeNewswire
Sanofi (NASDAQ: SNY) Set to Acquire Provention Bio (NASDAQ: PRVB) for $2.9 Billion
Provention Bio, Inc. (NASDAQ: PRVB) is engaged as a commercial-stage biopharmaceutical company, which is focused on the research, development and 
Via Spotlight Growth
Pfizer Officially Nabs Seagen For $43 Billion; Provention Soars On Sanofi Deal
Pfizer expects Seagen to add at least $10 billion to its topline in 2030. 
Via Investor's Business Daily
Why Provention Bio Stock Is Rocketing Past 52-Week Highs Today
Provention Bio Inc (NASDAQ: PRVB) shares are rocketing higher Monday after Sanofi (NASDAQ: SNY) announced plans to acquire the biopharmaceutical company. 
Via Benzinga
Why Is Provention Bio (PRVB) Stock Up 263% Today?
Provention Bio (PRVB) stock is rocketing higher on Monday following news that Sanofi (SNY) is acquiring the company for $2.9 billion. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting off the week with a breakdown of the biggest pre-market stock movers traders need to know about for Monday! 
Via InvestorPlace
Nasdaq Futures Climb Solidly After Past Week's Rout: Analyst Flags Key S&P 500 Support To Stay Above October Lows
After the market mayhem seen last week, some semblance of normalcy could return to Wall Street, thanks to the government’s move to assuage concerns in response to the banking crisis. 
Via Benzinga
Sanofi, AstraZeneca Tee Up A Rival To Pfizer In The Multibillion-Dollar RSV Race
These companies aren't working on a vaccine, but a monoclonal antibody. 
Via Investor's Business Daily
7 Blue-Chip Stocks to Buy for Quality-Focused Investors
With circumstances shaky in the market right now, concerned investors may want to consider blue-chip stocks to buy. 
Via InvestorPlace
Sanofi Could Be on a Roll With a Strong Performance and Its Latest FDA Approval
The French drug company got the nod for a hemophilia treatment. 
Via The Motley Fool
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
26 27 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.